| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models
|
| Manuscript Source |
Invited Conference Manuscripts |
| All Author List |
Nicha Wongjarupong, Gabriela M Negron-Ocasio, Roongruedee Chaiteerakij, Benyam Addissie, Essa Mohamed, Kristin C Mara, William S Harmsen, Paul J Theobald, Brian E Peters, Joseph G Balsanek, Melissa M Ward, Nasra Giama, Sudhakar Kundapur Venkatesh, Denise M Harnois, Michael R Charlton, Hiroyuki Yamada, Alicia Algeciras-Schimnich, Melissa R Snyder, Terry M Therneau and Lewis R. Roberts |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Mayo Clinic Center for Cell Signaling in Gastroenterology |
NIDDK P30DK084567 |
| Mayo Clinic Center for Clinical and Translational Science |
NCATS UL1 TR000135 |
| Wako Life Sciences, Inc. |
|
|
| Corresponding Author |
Lewis R. Roberts, MD, PhD, Doctor, Doctor, Full Professor, Professor, Research Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, United States. roberts.lewis@mayo.edu |
| Key Words |
alpha-fetoprotein; AFP-L3; des-gamma-carboxyprothrombin; BALAD; BALAD-2; Hepatocellular carcinoma; Liver transplant; Recurrence; Outcome |
| Core Tip |
BALAD score and BALAD-2 class incorporating alpha-fetoprotein (AFP), AFP-L3, and des-gamma-carboxyprothrombin are used to predict survival of patients with hepatocellular carcinoma. However, there were limited numbers of patients who received liver transplant in previous cohorts in which performance of the BALAD was studied. Our study showed that pre-transplant BALAD score and BALAD-2 class are useful for predicting outcome of hepatocellular carcinoma patients receiving liver transplant. However, a more predictive model uses the combination of all three biomarkers using the cut-offs from the BALAD score along with maximum tumor size at the time of transplant. |
| Publish Date |
2018-03-26 08:48 |
| Citation |
Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Pre-transplant tumor biomarkers show more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018; 24(12): 1321-1331 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i12/1321.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i12.1321 |
